Rituximab and bilateral HSV epithelial keratitis in a patient with mucous membrane pemphigoid

ConclusionsAlthough rituximab is a promising biologic agent for the treatment of autoimmune diseases, it bears the risk of reactivation of viral infections, including the onset of herpes simplex virus keratitis.
Source: Journal of Ophthalmic Inflammation and Infection - Category: Opthalmology Source Type: research